Labarthe D R, O'Fallon W M
JAMA. 1980 Jun 13;243(22):2304-10. doi: 10.1001/jama.243.22.2304.
To supplement several case-control studies questioning whether use of reserpine is associated with occurrence of breast cancer, we conducted a longitudinal study of nearly 2,000 hypertensive women residing in Rochester, Minn. Exposure to antihypertensive agents and subsequent incidence of breast cancer were ascertained. Expected numbers of cases, derived from local population data and from the Connecticut Tumor Registry, were compared with the numbers of cases observed in exposure groups of interest. No evidence was found of any association of reserpine use, thiazide use, or untreated hypertension with subsequent occurrence of breast cancer in these hypertensive women. In addition, several issues were investigated that warrant consideration in evaluating reports published to date, especially before conclusions are drawn as to the questionable contention that reserpine has caused breast cancer in women.
为补充几项病例对照研究（这些研究对利血平的使用是否与乳腺癌的发生有关提出质疑），我们对居住在明尼苏达州罗切斯特市的近2000名高血压女性进行了一项纵向研究。确定了她们对抗高血压药物的暴露情况以及随后乳腺癌的发病率。将根据当地人口数据和康涅狄格肿瘤登记处得出的预期病例数与在感兴趣的暴露组中观察到的病例数进行比较。在这些高血压女性中，未发现使用利血平、噻嗪类药物或未经治疗的高血压与随后发生乳腺癌之间存在任何关联。此外，还调查了几个问题，这些问题在评估迄今发表的报告时值得考虑，特别是在就利血平导致女性乳腺癌这一有争议的论点得出结论之前。
